ANAB
Price:
$13.97
Market Cap:
$425.09M
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody ...[Read more]
Industry
Biotechnology
IPO Date
2017-01-26
Stock Exchange
NASDAQ
Ticker
ANAB
According to AnaptysBio, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -2.31. This represents a change of -47.49% compared to the average of -4.40 of the last 4 quarters.
The mean historical PE Ratio of AnaptysBio, Inc. over the last ten years is -20.16. The current -2.31 PE Ratio has changed 1.05% with respect to the historical average. Over the past ten years (40 quarters), ANAB's PE Ratio was at its highest in in the December 2014 quarter at 838.55. The PE Ratio was at its lowest in in the June 2015 quarter at -7653.71.
Average
-20.16
Median
-21.10
Minimum
-72.48
Maximum
68.13
Discovering the peaks and valleys of AnaptysBio, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 552.31%
Maximum Annual PE Ratio = 68.13
Minimum Annual Increase = -165.35%
Minimum Annual PE Ratio = -72.48
Year | PE Ratio | Change |
---|---|---|
2023 | -3.52 | -48.02% |
2022 | -6.78 | -59.32% |
2021 | -16.67 | -43.44% |
2020 | -29.47 | 552.31% |
2019 | -4.52 | -82.30% |
2018 | -25.53 | -61.47% |
2017 | -66.26 | -8.59% |
2016 | -72.48 | 62.82% |
2015 | -44.52 | -165.35% |
2014 | 68.13 | -138.00% |
The current PE Ratio of AnaptysBio, Inc. (ANAB) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-8.99
5-year avg
-12.19
10-year avg
-20.16
AnaptysBio, Inc.’s PE Ratio is greater than Deciphera Pharmaceuticals, Inc. (-11.74), greater than Crinetics Pharmaceuticals, Inc. (-15.55), greater than Rhythm Pharmaceuticals, Inc. (-13.18), greater than Kura Oncology, Inc. (-3.93), less than CytomX Therapeutics, Inc. (6.71),
Company | PE Ratio | Market cap |
---|---|---|
-11.74 | $2.21B | |
-15.55 | $5.00B | |
-13.18 | $3.44B | |
-3.93 | $695.21M | |
6.71 | $85.30M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like AnaptysBio, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like AnaptysBio, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is AnaptysBio, Inc.'s PE Ratio?
How is the PE Ratio calculated for AnaptysBio, Inc. (ANAB)?
What is the highest PE Ratio for AnaptysBio, Inc. (ANAB)?
What is the 3-year average PE Ratio for AnaptysBio, Inc. (ANAB)?
What is the 5-year average PE Ratio for AnaptysBio, Inc. (ANAB)?
How does the current PE Ratio for AnaptysBio, Inc. (ANAB) compare to its historical average?